Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI

NCT00406016 | Completed Phase 1

• 1 other identifier: CATI355A2102
• Study Type: interventional
• Target: 52
• Locations: 3 countries
• Sites: 14

Brief Summary

This study will evaluate the acute safety, tolerability, feasibility and pharmacokinetics of 6 dose regimens of ATI355 in acute spinal cord injury patients

Conditions

Acute Spinal Cord Injury

Keywords

Acute spinal cord injury;

Outcome Measures

Primary Outcomes (1)

• Feasibility, Safety and Tolerability of a continuous intrathecal (i.t.) infusion or i.t. repeated bolus injections of ATI355 in patients with acute spinal cord injury at every visit and Assessment of serum and CSF pharmacokinetics at predefined visits.

  1 year

Secondary Outcomes (2)

• Immunogenicity of ATI355 in acute spinal cord injury patients up to one year.

  1 year

• Early potential signal of efficacy by the American Spinal Cord Injury Association (ASIA) protocol and pharmacodynamic changes assessed by electrophysiology tests for up to one year.

  1 year

Study Arms (1)

1

EXPERIMENTAL

Drug: ATI355

Interventions

ATI355 DRUG

1

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Acute spinal cord injury paraplegic and tetraplegic patients with confirmed classification of ASIA A (C5 ≤ lesion ≤ T12; 4-14 days post-injury (i.e. study drug treatment must begin 4-14 days post injury) for paraplegic patients and for those tetraplegic patients who do not require artificial respiration at time of treatment initiation within the 4-14 days time interval. In those tetraplegic patients who still require artificial respiration in the 4-14 days time interval treatment can be initiated up to 60 days post-injury as soon as the patient is weaned off the respiratory machine.)
• Tetraplegic patients who were initially diagnosed as ASIA A (neurologically complete lesion) at screening and turned into ASIA B (neurologically incomplete lesion) at baseline.
• Hemodynamically stable (at baseline).
• For female patients of child bearing potential, written agreement to abstain from intercourse during the first 12 weeks of the study and then subsequent use of a double-barrier local contraception, i.e. intra-uterine device plus condom, or spermicidal gel plus condom for up to one year post study drug treatment. Patients must receive documented counseling on contraceptive measures.
• For Cohort 5: Acute spinal cord injury tetraplegic patients with confirmed classification of ASIA A: Cervical lesions (C5 ≤ lesion ≤ T1). 4-28 days post-injury (i.e. study drug treatment must begin 4-28 days post injury). Tetraplegic patients who are allowed to start treatment are those who either do not require mechanical ventilation or who do not completely depend on mechanical ventilation but show some degree of spontaneous ventilation. Only those modes of ventilation where the patient must initiate all breaths are allowed (e.g. continuous positive airway pressure \[CPAP\]).

You may not qualify if:

• Complete anatomical transection confirmed by MRI or trauma caused by ballistic or other injury that directly penetrates the spinal cord including gunshot and knife wounds.
• Magnetic Resonance Imaging (MRI) indicating complete obstruction of the intrathecal space.
• Presence of one of the following:
• multiple spinal cord lesions
• cauda equina damage
• major brachial or lumbar plexus damage/trauma
• significant head trauma (e.g. cortical damage/lesion), or other injury that was, in the opinion of the investigator, sufficient to interfere with the assessment of the spinal cord function or otherwise compromise the validity of the patient's data.
• Other significant preexisting or current systemic disease such as lung, liver (exception: history of uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency (including human immunodeficiency virus \[HIV\]) or kidney disease; or active malignancy or any other condition as determined by history or laboratory investigation that could cause a neurological deficit including syphilis, myelopathy, clinically relevant polyneuropathy, etc.
• History of meningitis, meningoencephalitis, epilepsy or life-threatening allergic or immune-mediated reaction.
• History of or current autoimmune disease or an acute episode of Guillain-Barre syndrome.
• Patients with uncontrolled bleeding diathesis and/or on concomitant treatment with coumarin anticoagulant.
• Presence of any unstable medical or psychiatric condition (defined by the Diagnostic and Statistical Manual of Mental Disorders-IV \[DSM-IV\]) that could reasonably have been expected to subject the patient to unwarranted risk from participation in the study or result in a significant deterioration of the patient's clinical course.
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (\> 5 mIU/ml).
• Hemoglobin levels below 8.0 g/dl and/or patients who required greater than 10 (ten) blood transfusions since the acute injury
• Patients with concomitant treatment with Metamizole from Screening until end of Follow Up phase

Sponsors & Collaborators

• Novartis: lead

Study Sites (14)

Novartis Investigative site

Calgary, Canada

Location

Novartis Investigative site

Montreal, Canada

Location

Novartis Investigative site

Toronto, Canada

Location

Novartis Investigative site

Vancouver, Canada

Location

Novartis Investigative site

Bad Wildungen, 34537, Germany

Location

Novartis Investigative site

Bayreuth, 09445, Germany

Location

Novartis Investigative site

Bochum, 44789, Germany

Location

Novartis Investigative site

Hamburg, 21033, Germany

Location

Novartis Investigative site

Heidelberg, 69118, Germany

Location

Novartis Investigative site

Karlsbad-Lagensteinbach, 76307, Germany

Location

Novartis Investigative site

Murnau am Staffelsee, 82418, Germany

Location

Novartis Investigative site

Tübingen, 72076, Germany

Location

Novartis Investigative site

Ulm, 89081, Germany

Location

Novartis Investigative site

Zurich, 8008, Switzerland

Location

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2006
• First Posted: December 4, 2006
• Study Start: May 1, 2006
• Primary Completion: September 1, 2011
• Study Completion: September 1, 2011
• Last Updated: February 11, 2020

Record last verified: 2011-11

Locations

DE (9); CH (1); CA (4)